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Broadly neutralizing monoclonal antibodies to HIV-1
are rare but invaluable for vaccine design. 4E10 is the
broadest neutralizing antibody known and recognizes
a contiguous and highly conserved epitope in the
membrane-proximal region of gp41. The crystal struc-
ture of Fab 4E10 was determined at 2.2 Å resolution
in complex with a 13-residue peptide containing the
gp41 core epitope (NWFDIT). The bound peptide
adopts a helical conformation in which the key con-
tact residues, TrpP672, PheP673, IleP675, and ThrP676,
map to one face of the helix. The peptide binds in
a hydrophobic pocket that may emulate its potential
interaction with the host cell membrane. The long
CDR H3 of the antibody extends beyond the bound
peptide in an orientation that suggests that its apex
could contact the viral membrane when 4E10 is
bound to its membrane-proximal epitope. These
structural insights should assist in the design of im-
munogens to elicit 4E10-like neutralizing responses.
Introduction
The success of immunoprophylaxis in animal models
using HIV-1-neutralizing monoclonal antibodies sug-
gests that, if neutralizing antibodies could be generated
by an appropriate vaccine, they would provide substan-
tial benefit (Ferrantelli and Ruprecht, 2002; Mascola,
2003; Burton et al., 2004). However, the goal of designing
immunogens that elicit neutralizing antibodies against
multiple isolates of HIV-1 has been extraordinarily difficult
to achieve. The vast majority of anti-HIV-1 antibodies
elicited either by immunization or during natural infec-
tion have limited or no crossneutralizing activity to other
HIV-1 isolates and typically bind to nonconserved epi-
topes or epitopes that are poorly exposed on infectious
virions. Only a handful of potent and broadly crossreac-
tive human monoclonal antibodies (mAbs) have been*Correspondence: burton@scripps.edu (D.R.B.); wilson@scripps.
edu (I.A.W.)identified to date against HIV-1 primary isolates and in-
clude mAbs b12, 2G12, 2F5, and 4E10. These rare
mAbs have been derived from HIV-1-infected patients
and target conserved but distinct epitopes on gp120 or
gp41, the HIV-1 envelope (Env) glycoproteins responsi-
ble for mediating HIV entry into human cells (Weissenh-
orn et al., 1997; Chan et al., 1997; Kwong et al., 1998;
Wyatt and Sodroski, 1998; Gallo et al., 2003). mAb b12
binds to the recessed CD4 binding site on gp120
(Saphire et al., 2001), whereas mAb 2G12 recognizes a
unique cluster of oligomannose sugars on the gp120
outer domain (Calarese et al., 2003). mAbs 4E10 and
2F5 recognize adjacent and highly conserved contigu-
ous epitopes in the extreme C-terminal, membrane-
proximal region of gp41 (Figure 1), indicating that gp41
is not completely masked from Ab recognition by
gp120. The 2F5 epitope is centered around the se-
quence ELDKWA (Muster et al., 1993; Pai et al., 2000;
Ofek et al., 2004), whereas 4E10 recognizes an epitope
containing the sequence NWF(D/N)IT (Zwick et al.,
2001b, 2005; Kunert et al., 2004) in a Trp-rich region of
gp41 immediately C-terminal to the 2F5 epitope. Simul-
taneous targeting of multiple conserved epitopes on
HIV is likely to be the best strategy for vaccine develop-
ment to maximize the breadth of protection (Zwick et
al., 2001b; Kitabwalla et al., 2003). As a single agent,
4E10 is the broadest HIV-1-neutralizing mAb described
to date with activity against isolates from most HIV-1
clades, including A, B, C, D, E, and G, albeit sometimes
with less potency than the other three more clade-
restricted mAbs described above (Binley et al., 2004).
The conserved C-terminal region of the gp41 extra-
cellular domain that encompasses the 4E10 and 2F5
epitopes is critical for Env-mediated membrane fusion
and virus infectivity (Salzwedel et al., 1999; Munoz-Bar-
roso et al., 1999). Alanine mutation of three of five
highly conserved tryptophan residues (Trp666, Trp670,
and Trp672; numbered according to the HXB2 isolate
sequence) in this membrane-proximal region greatly re-
duces viral entry (Salzwedel et al., 1999). Moreover, the
induction of membrane leakage by a peptide corre-
sponding to this Trp-rich region (Suarez et al., 2000) im-
plies that this region may be directly involved in mem-
brane disruption during the fusion process. However,
this notion has been challenged by another mutagene-
sis study which suggests that the membrane-proximal
region instead provides a flexible arm to gp41 to allow
membrane fusion (Dimitrov et al., 2003). Overall, the
conserved membrane-proximal region of gp41 appears
to be highly promising for vaccine development, espe-
cially since it is the target of two (4E10 and 2F5) of the
four most broadly neutralizing anti-HIV mAbs.
The three-dimensional structure of the Trp-rich mem-
brane-proximal region of gp41 was previously investi-
gated by NMR spectroscopy using a synthetic peptide
(KWASLWNWFNITNWLWYIK) (Schibli et al., 2001). In
dodecylphosphocholine micelles, the Trp-rich region
has a helical structure with the Trp residues forming
a “collar” around the helix axis, parallel to the water-
dodecylphosphocholine interface of the micelle. How-
Immunity
164Figure 1. Schematic Representation of gp41
Important functional regions include the fu-
sion peptide (FP, purple box), the N- and
C-terminal heptad repeat regions (NHR,
green box, and CHR, red box, respectively),
and the transmembrane region (TM, yellow
box). The location and sequence of the Trp-
rich region are indicated with the core 2F5
and 4E10 epitopes shown in red, and the se-
quence contained within the peptide used in
this study is underlined. Sequence number-
ing follows strain HXB2. The various do-
mains are not drawn to scale.ever, the precise orientation of this region in the natural t
tcontext of the native gp120-gp41 trimer and how it
might rearrange during the fusion process remain un- P
Cknown. To examine the interaction of 4E10 with its epi-
tope on gp41 at the atomic level, we determined the (
fcrystal structure of Fab 4E10 in complex with a soluble
synthetic 13-residue peptide (KGWNWFDITNWGK) (Zwick t
det al., 2001a) that encompasses the 4E10 epitope and
corresponds to the W670-W678 consensus group M t
msequence of gp160. The structure of this complex re-
veals the epitope conformation recognized by 4E10





lStructure Determination of a Fab
4E10-Peptide Complex (
To examine the interaction of 4E10 with the Trp-rich
membrane-proximal region of gp41, the crystal struc- T
Fture of a Fab 4E10-peptide epitope complex was deter-
mined at 2.2 Å resolution. The 4E10 epitope is con- l
atained within the 13-residue peptide (LysP668 GlyP669
TrpP670 AsnP671 TrpP672 PheP673 AspP674 IleP675 ThrP676 r
aAsnP677 TrpP678 GlyP679 LysP680; numbered according to
the HXB2 isolate sequence with a P chain identifier) r
athat was previously shown to bind 4E10 (in that study,
the peptide was named KGND) (Zwick et al., 2001a). (
bThe Lys and Gly residues at either end of this peptide
were added to increase peptide solubility in water. r
uHuman IgG3 4E10 was originally isolated from a
clade B HIV-1-positive individual (Buchacher et al.,
T1994). Fab 4E10 was obtained by papain digestion of
the recombinant IgG1(κ) 4E10, produced in Chinese G
Phamster ovary (CHO) cells (Kunert et al., 2004). The
complex of Fab 4E10 and peptide was achieved by a
fovernight incubation of the Fab at 4°C with a five times
molar excess of peptide. Crystals grew after about one O
eweek as clusters of thin plates, which were carefully
separated into individual plates for X-ray data collec- (
ction. The data were indexed in space group C2 with two
4E10-peptide complexes per asymmetric unit (61.5% o
rsolvent content and Matthews’ coefficient of 3.2 Å3
Da−1). The structure was determined by molecular re- a
splacement using Fab 48G7, a catalytic antibody (Pro-
tein Data Bank [PDB] entry 1HKL), as the initial model G
hand was then refined to a resolution of 2.2 Å with
Rcryst = 21.7%, and Rfree = 26.0% (Table 1). The final c
omodel contains Fab residues L1-L212, H1-H232 (Fab
residues are numbered according to standard conven- vion [Kabat et al., 1991] with light and heavy chain iden-
ifiers L and H, respectively) and peptide residues
669–P680. Heavy-chain C-terminal residues (SerH229,
ysH230, AspH231, and LysH232) were visible in one Fab
molecule 1). Electron density omit maps clearly de-
ined the location and conformation of the peptide in
he 4E10 binding site (Figure 2A). The only peptide resi-
ue which had no interpretable electron density was
he N-terminal LysP668, which was not included in the
odel.
The Fab 4E10-peptide complex model has good ge-
metry with only AlaL51, which is in a highly conserved
turn as in most antibody structures (Stanfield et al.,
999), in the disallowed region of the Ramachandran
lot (Table 1). As expected, the two molecules in the
symmetric unit are similar, with rms deviations (Cα)
ess than 0.4 Å. Only the complex with lower B values
molecule 1) will be described here.
he Structure of Fab 4E10
ab 4E10 has the canonical β sandwich immunoglobu-
in fold with an elbow angle of 193° in both independent
ntibody molecules. The complementarity determining
egions (CDRs) or hypervariable loops L1, L2, L3, H1,
nd H2 belong to canonical classes 2, 1, 1, 1, and 2,
espectively, as determined from the length, sequence,
nd conformation of the loops (Al-Lazikani et al., 1997)
Figures 3A and 3B). CDR H3 bends away from the
inding site to allow interaction of its base and central
esidues with the C-terminal region of the peptide (Fig-
re 3B).
Antibody 4E10 has a long CDR H3 (GluH95 GlyH96
hrH97 ThrH98 GlyH99 TrpH100 GlyH100A TrpH100B LeuH100C
lyH100D LysH100E ProH100F IleH100G GlyH100H AlaH100I
heH100J AlaH101 HisH102) with a ten amino acid insert
fter residue 100. Such long CDR H3 loops are also
ound in other HIV-1 mAbs, such as 2F5 (Pai et al., 2000;
fek et al., 2004), Z13 (Zwick et al., 2001a), b12 (Saphire
t al., 2001), 447-52D (Stanfield et al., 2004), and 17b
Kwong et al., 1998) and may facilitate access to con-
ave or relatively inaccessible sites. In addition, the tip
f the H3 loop of 4E10 is composed of mainly nonpolar
esidues (GlyH99, TrpH100, GlyH100A, TrpH100B, LeuH100C,
nd GlyH100D) (Figure 3C) that form a quite hydrophobic
urface. As only two of these residues (LeuH100C and
lyH100D; Table 2) contact the peptide epitope, the other
ydrophobic residues are positioned such that they
ould interact with the adjacent viral membrane and/or
ther residues of gp41. The five Gly residues may pro-
ide the loop with the appropriate conformational flexi-
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165Table 1. X-Ray Diffraction Data and Refinement Statistics for the 4E10-Peptide Complex
Crystal Features
Space group C2
No. of molecules of complex per asymmetric unit 2
Unit cell parameters (Å, °) a = 157.3, b = 45.1, c = 198.5, β = 113.8
Data Quality
Resolution (Å)a 50.00–2.20 (2.28–2.20)
No. of observations 198,794
No. of unique reflections 61,572
Mosaicity (°) 0.35
Completeness (%)a 93.0 (61.4)
Multiplicitya 3.2 (2.2)
I/σ(I)a 16.7 (2.3)




No. of protein atoms 6907
No. of water molecules 612
Average B value (Å2)
Molecule 1 (heavy, light, peptide) 22.2, 19.5, 28.3
Molecule 2 (heavy, light, peptide) 41.0, 46.5, 33.8
Water molecules 36.2
Rms deviation for bond lengths (Å) 0.005
Rms deviation for bond angles (°) 1.3
Ramachandran plot
Most favored regions (%) 87.2
Additional allowed regions (%) 12.4
Generously allowed regions (%) 0.1
Disallowed regions (%) 0.3d
a Values in parentheses correspond to the highest resolution shell.
b Rsym = [ShSi|Ii(h) − <I(h)>|/ShSiIi(h)] × 100, where <I(h)> is the mean of the I(h) observation of reflection i.
c R = Shkl |Fo − Fc|/Shkl |Fo|. Rfree was calculated as R but using only 5% of data reserved for the crossvalidation.
d The only residue present in the disallowed region is AlaL51, which is in a conserved γ turn, as observed in most antibody structures (Stanfield
et al., 1999).bility, while the Trp residues may facilitate interactions
with hydrophobic regions in or around the membrane-
proximal region of gp41, including the viral membrane.
This remarkably hydrophobic flat tip resembles the
structure described for the H3 loop of 2F5 (Ofek et al.,
2004), another HIV-1-neutralizing antibody that also
binds to the membrane-proximal region of gp41.
Another noteworthy characteristic of 4E10 is the re-
markable hydrophobicity of its combining site (Figure
3D), which is derived in part from the H3 loop as well
as from an unusually hydrophobic H2 loop (GlyH50
ValH51 IleH52 ProH52A LeuH53 LeuH54 ThrH55 IleH56 ThrH57
AsnH58 TyrH59 AlaH60). Nevertheless, the amino acid
composition, particularly of L1, L3, and part of H3, con-
tributes sufficient hydrophilic interactions to stabilize
the otherwise exposed binding site.
The Structure of the 4E10 Epitope
The 13-residue peptide is bound to Fab 4E10 in a helical
conformation (Figures 2–4), as found for a 19-residue
peptide corresponding to the Trp-rich membrane-proxi-
mal region of gp41 in membrane-mimetic dodecylphos-
phocholine micelles by NMR spectroscopy (Schibli et
al., 2001). The 13-residue peptide has an α-helical con-
formation from AspP674 to LysP680 preceded by a short
310 helix (AsnP671 and TrpP672) and an extended struc-
ture (GlyP669 and TrpP670) at the N terminus (Figures 2Band 2C). The transition from 310 helix to α helix occurs
at PheP673, where its carbonyl oxygen makes a water-
mediated hydrogen bond to the backbone nitrogen of
AsnP677 (Figure 2B), the i+4 residue from PheP673, in an
almost α-helical manner. The 310 helix has been sug-
gested to act as a folding intermediate in α-helix forma-
tion. The helical conformation creates an amphipathic
structure with a narrow polar face (defined by AsnP671,
AspP674, AsnP677, and LysP680) and a large hydrophobic
face (TrpP672, PheP673, IleP675, ThrP676, TrpP678, and
GlyP679) (Figures 2C and 2D). Residue LysP680, which is
part of a solubility tag, corresponds in position to the
universally conserved Trp680 in the gp41 sequence and
is located between these two faces.
In complexes between peptides and antibodies, β-turns
are the predominant secondary structure of the bound
peptide (Stanfield and Wilson, 1995). Thus, the helical
conformation of the peptide bound to 4E10 is highly
unusual. To date, only two other examples of crystal
structures of complexes between helical peptides and
antibodies have been deposited in the Protein Data
Bank (PDB): an anti-interleukin 2 Fab in complex with
an antigenic nonapeptide with seven residues in an
α-helical conformation (PDB ID code 1F90) (Afonin et
al., 2001) and antibody C21 in complex with its epitope
on P-glycoprotein, where all 11 peptide residues form
an α helix (PDB ID code 2AP2) (van den Elsen et al.,
Immunity
166Figure 2. Structure of the Peptide Bound to
Fab 4E10
The peptide sequence is KGWNWFDITNWGK
and encompasses the 4E10 epitope.
(A) Stereo view of the peptide structure su-
perimposed on the σA-weighted Fo − Fc
electron density omit map contoured at 4σ.
Clear density is evident for all peptide resi-
dues, except for the two added residues at
the N terminus. Part of the heavy (gray) and
light (pink) chains of the antibody are dis-
played.
(B and C) Side (B) and top view (C) of the
peptide helix. Hydrogen bonds involved in
stabilization of the helical conformation are
shown as dotted lines.
(D) Representation of the peptide helical
wheel. The residues on the polar face are in
red, and the hydrophobic face is black.1999). Thus, this helical conformation is expected to a
tmimic its cognate structure in gp41, particularly as
4E10 binds to and neutralizes HIV-1. w
tAntibody 4E10 binds with approximately 4-fold
higher affinity to soluble recombinant gp41 than to the l
tsynthetic peptide (data not shown), as determined by
enzyme-linked immunosorbent assays (ELISA). The re-
pduced affinity of 4E10 for the peptide is likely due to
lack of appropriate flanking residues, such as TrpP680 m
sor perhaps other more distal regions of gp41, or to the
inherent flexibility of the short, linear peptide. Neverthe- b
oless, the key contact residues between 4E10 and the
peptide are likely to be the same as those with the core (
tepitope on gp41.
m
Structural Basis for 4E10 Specificity
dSpecific antibody-antigen recognition comes from ste-
fric and chemical complementarity between antigen and
pantibody. The Fab 4E10 combining site is a largely hy-
bdrophobic cavity (Figure 3D) that allows close fit of the
damphipathic peptide. The antibody surface area buried
tby the peptide is approximately 580 Å2, whereas the
pcorresponding area on the peptide is about 529 Å2. Al-
hthough these values are comparable to those found in
oother Fab-peptide complexes (Stanfield and Wilson,
a1995), the 4E10 peptide additionally buries an extra
r360 Å2 of its surface due to crystal packing. In the crys-
atal, the two peptide molecules are adjacent to each other
and related by a two-fold crystallographic symmetry txis (Figures 3E and 3F). This supersecondary interac-
ion of the two peptide chains (Figure 3F) combines
ith the antibody interaction to almost completely bury
he largely hydrophobic peptide and perhaps mimics a
ow-energy conformation in the intact gp41 oligomer or
hrough association with the viral membrane.
Fab 4E10 uses five of its six CDR loops to bind the
eptide; CDR L2 is not used and CDR L1 makes only
inor contacts (Figure 3B). Eight hydrogen bonds, one
alt bridge, and 98 van der Waals contacts are made
etween peptide and Fab residues from CDRs L1 (4%
f total contacts), L3 (28%), H1 (8%), H2 (41%), and H3
19%) (Table 2). Ten additional hydrogen bonds be-
ween peptide and Fab residues are mediated by water
olecules buried at the Fab-peptide interface.
The extent and nature of the Fab-peptide interactions
efine the relative importance of each peptide residue
or complex formation. In a helical conformation, the
eptide backbone cannot easily engage in hydrogen
onding to the Fab because of the intrapeptide hy-
rogen bonding along the helix. The peptide recogni-
ion then depends mainly on interactions in which the
eptide side-chain knobs from the helix intercalate into
oles on the antibody surface. The helical conformation
f the bound peptide places the side chains of TrpP672
nd PheP673 on the same side of the peptide, and these
esidues, along with IleP675, ThrP676, and LysP680, form
n extensive hydrophobic face that intimately contacts
he Fab (Figure 4). The side chains of TrpP672 and
Anti-HIV Antibody 4E10 Recognizes a Helical Motif
167Figure 3. The Antigen Binding Site of Fab 4E10
(A and B) The CDRs L1, L2, L3, H1, H2, and H3 are highlighted in the Fab 4E10-peptide complex. The light chain (pink) with CDRs L1 (dark
blue) and L3 (green) and the heavy chain (gray) CDRs H1 (orange), H2 (magenta), and H3 (red) contact the peptide (yellow). CDR L2 (cyan)
does not contact antigen.
(C) Conformation of the H3 loop in the peptide-bound structure of Fab 4E10. The H3 loop (gray backbone with pink side chains) is rich in Gly
and Trp residues. The bound peptide (yellow) in the complex structure is shown for reference.
(D) Electrostatic potential surface of Fab 4E10 with bound peptide. Negatively charged regions are red, positively charged regions are blue,
and neutral regions are white (±15 kV potential range). The peptide (yellow) binds in a shallow hydrophobic cavity on the antibody.
(E) Overall view of two Fab 4E10-peptide complexes in the crystal unit cell. The crystal contacts in this region are close to the antigen binding
site of Fab 4E10 (heavy chains are gray and green; light chains are salmon and blue). The peptides (yellow and purple chains) are located in
the interface between the two related Fab molecules.
(F) Interaction of two peptide chains in the unit cell show the close interdigitation of their indole side chains, which may reflect a biologically
important interaction of the peptide Trp residues with the viral membrane.PheP673 insert into a pocket in the antibody-combining
site, where they form a cluster of aromatic rings with
Fab residues TyrL91, TrpH47, and PheH100J (Figures 4A
and 4B). In addition to the 37 van der Waals contacts,
the main chain and side chain of TrpP672 hydrogen bond
to SerL94 and IleH56, respectively (Table 2 and Figures
4A and 4B). The TrpP672 contacts represent 36% of thetotal contacts between Fab 4E10 and peptide (Table 2),
making it the most important residue in the antibody-
peptide interaction; the majority of these contacts
(85%) are with CDR H2 (residues GlyH50, ValH51, IleH52,
IleH56, and AsnH58). The next key peptide residues are
ThrP676 and PheP673, which make 18% and 14% of the
total contacts with the Fab, respectively. PheP673 works
Immunity
168aTable 2. Direct Contacts between Fab 4E10 and Peptide
4
van der Waals Contacts c
Peptide b
Residue Fab 4E10 Residue m
mAsnP671 GlyL92, GlnL93, SerL94
TrpP672 SerL94, AlaH33, GlyH50, ValH51, IleH52, IleH56, AsnH58 m
PheP673 TyrL91, SerL94, TrpH47, PheH100J v
AspP674 LysL32 i
IleP675 lleH52, IleH56
eThrP676 ThrH31, TyrH32, AlaH33, IleH52, GluH95, ProH100F
TAsnP677 ProH100F
iLysP680 LeuH100C, GlyH100D, ProH100F
mHydrogen Bond and Salt Bridge Contacts
4
Peptide Atom Fab 4E10 Atom Distance (Å) t
TrpP670–O SerL94–Oγ 3.4 o
AsnP671–Oδ1 TyrL91–O 2.9 p
AsnP671–Nδ2 SerL94–N 3.2 bTrpP672–N SerL94–Oγ 3.2
πTrpP672–N1 IleH56–O 3.2
aAspP674–Oδ1 LysL32–Nξ 3.4
ThrP676–Oγ1 GluH95–O1 3.0 s
ThrP676–Oγ1 GluH95–O2 2.8 F
LysP680–Nξ LeuH100C–O 2.7 h
T
4
cooperatively with TrpP672 to form the cluster of aro- t
matic rings in the binding site (Figure 4B). In addition c
to several van der Waals contacts, the hydroxyl side G
chain of ThrP676 hydrogen bonds to the carboxyl side s
chain of GluH95 (Table 2 and Figures 4A and 4C). ThrP676 i
along with LysP680 are the peptide residues with the w
most interactions with the H3 loop (Table 2). Even d
though IleP675 is responsible for only 6% of the contacts w
between 4E10 and the peptide, its side chain stacks
with the corresponding aliphatic side chains of IleH52 4
and IleH56 to create a cluster of isoleucines on the edge m
of the antibody-combining site (Figures 4A and 4C). i
Mutagenesis of HIV-1 has recently shown that TrpP680 T
is important for 4E10 neutralization (Zwick et al., 2005). h
In the peptide studied here, a Lys rather than a Trp was 1
substituted at position 680 to increase peptide solubil-
t
ity. Because this residue is in an α helix, the change
I
from a Lys to a Trp side chain should not affect the
o
helical conformation. However, this change could affect
tthe interactions that this residue makes with the anti-
bbody. Thus, to explore the structural role of TrpP680 in
bthe binding site, TrpP680 was modeled in place of
fLysP680 in the preferred rotamer that maximizes con-
mtacts with 4E10 (Figure 4D). In this conformation, the
mN1 atom of TrpP680 would hydrogen bond to the car-
mbonyl oxygen of LeuH100C, which corresponds to the
ohydrogen bond interaction of the Nξ atom of LysP680
mwith LeuH100C in the crystal structure. In addition,
eTrpP680 would pack with TyrH32 and ProH100F (Figure 4D),
gforming a second cluster of aromatic residues in the
fantibody-combining site. All of these proposed con-
rtacts would place TrpP680, together with TrpP672,





cThe crystal structure of Fab 4E10, the most broadly
neutralizing HIV mAb yet described, was determined as 2complex with a 13-residue peptide containing the
E10 epitope on gp41. The structural analysis of the
ontributions made by each peptide residue to 4E10
inding reveals the key epitope residues which comple-
ent and extend the results obtained from epitope
apping (Zwick et al., 2001a; Stiegler et al., 2001) and
utagenesis experiments (Zwick et al., 2005). Pre-
iously, 4E10 was mapped to a linear epitope compris-
ng residues NWF(D/N)IT (Zwick et al., 2001a; Stiegler
t al., 2001) on the 671–679 Trp-rich region of gp41.
he crystal structure of the Fab 4E10-epitope complex
llustrates that TrpP672, PheP673, IleP675, and ThrP676
ake the greatest number of selective contacts with
E10 (Figure 4 and Table 2), which presumably dictate
he high affinity of 4E10 for the epitope. The side chains
f TrpP672 and PheP673 (and probably TrpP680; a Lys was
resent at this position in the peptide used here) are
uried in the binding site and are involved in aromatic
-stacking interactions. The most important residue for
ntibody-peptide binding is TrpP672, which alone is re-
ponsible for 36% of the total contacts between the
ab and the peptide. In comparison, IleP675 and ThrP676
ave a secondary role in defining 4E10 specificity.
hrP676 can be replaced by a serine without affecting
E10 binding, and Ser is found in many HIV isolates
hat are neutralized by 4E10. Such a Thr/Ser change
an maintain the hydrogen bond with CDR H3 residue
luH95. On the other hand, IleP675, which is highly con-
erved and forms part of a cluster of three isoleucines
n the binding site, is not involved in as many contacts
ith 4E10 and could perhaps be replaced by other me-
ium-size hydrophobic residues, such as Leu or Val,
ithout any drastic decrease in 4E10 affinity for gp41.
The Fab 4E10-epitope structure demonstrates why
E10 is very broadly neutralizing. First, the WFXI(T/S)
otif, where X does not play a major role in 4E10 bind-
ng, appears to be very conserved in all HIV-1 viruses.
he absolutely conserved residue Trp672 is believed to
ave a crucial role in virus infectivity (Salzwedel et al.,
999). Second, the somewhat more variable residues
hat immediately flank the conserved TrpP672, PheP673,
leP675, and Thr/SerP676 are located on the opposite side
f the helical epitope and are involved in very few con-
acts with the antibody. These variable residues might
e masked in the interface of a gp41 oligomer or em-
edded in the viral membrane (Figure 5). However, the
act that several HIV isolates with the same 4E10 mini-
al epitope are differentially neutralized with orders of
agnitude difference in potency (Binley et al., 2004)
ay imply that the 4E10 epitope is not equally exposed
n all viruses, with perhaps differences in Env confor-
ation or infection kinetics affecting accessibility to the
pitope. Alternatively, other regions of gp41 or even
p120 might also interact with 4E10. The 580 Å2 of sur-
ace area buried in the combining site is inside the
ange typically seen for Fabs binding peptides (usually
00–700 Å2) (Stanfield and Wilson, 1995); however,
ome available surface in the combining site indicates
hat residues outside of the core epitope could be in-
olved in binding. This possibility invites further experi-
ental investigation. Furthermore, denaturation of re-
ombinant gp41 reduces the binding of 4E10 but not of
F5 (Zwick et al., 2001a) and provides further support
Anti-HIV Antibody 4E10 Recognizes a Helical Motif
169Figure 4. Contacts between Fab 4E10 and Residues of Its Epitope
Hydrogen bonds are shown as dotted lines. Light, heavy, and peptide chains are shown in pink, gray, and yellow, respectively.
(A) Stereo view of the antigen binding site.
(B) Contacts between Fab 4E10 and key peptide residues TrpP672 and PheP673.
(C) Contacts between Fab 4E10 and key peptide residues IleP675 and ThrP676.
(D) Contacts between Fab 4E10 and key peptide residues LysP680 (for solubility) and modeled TrpP680 (green) that represents the actual













































Figure 5. Structural Considerations of Antibody Recognition of the d
Membrane-Proximal Region of gp41 a
d(A) CDR H3 residues not in contact with antigen are colored in red
on the molecular surfaces of 4E10 and 2F5 (PDB entry 1TJI). The
Eequivalent CDR H3 residues colored in red have been seen to con-
tact antigen in a survey of 26 antibody complex structures (Mac-
FCallum et al., 1996). This shows that 4E10 and 2F5 might contact
Radditional gp41 or gp120 residues or, more likely, the viral mem-
obrane when interacting with intact virus. The peptide is displayed
for reference.
(B) Model for the interaction between 4E10 (gray) and its mem-
pbrane-proximal epitope on gp41. Many constraints are imposed on
fthe 4E10 epitope in the context of the virus, including the proximity
wof both the viral membrane and the neighboring subunits of the
ttrimeric envelope spike (not shown). The peptide epitope (yellow),
tthe CDR H3 loop (red tube with green side chains), and the mod-
meled Tyr-Ile-Lys residues (orange) that link the peptide epitope re-
agion to the modeled gp41 transmembrane domain (purple) are all
cin close proximity to the surface of the membrane. Certain Trp resi-
edues of the peptide, i.e., Trp678, Trp680, and Trp670, could be in-
ovolved in intimate membrane interactions, e.g., if the 4E10 epitope
abecomes embedded in the membrane interface with its helical axisor the importance of the helical epitope conformation
or mAb 4E10 binding.
The CDR H3 loop of 4E10, as for 2F5, displays a large
urface not involved in antigen contact (Figure 5A). A
ore typical situation has the CDR H3 in contact with
ntigen throughout most of its length (MacCallum et al.,
996). This raises the possibility that the CDR H3 loops
f 4E10 and 2F5 could make further contacts with the
iral membrane (Figure 5B) or with other gp41 or gp120
esidues in the context of the intact virus. Additionally,
he size, hydrophobic character, and glycine-rich com-
osition of the CDR H3 of 4E10 may be an important
eature to facilitate interaction with the membrane-
roximal 4E10 epitope. Five Gly and two Trp residues
re present among the 18 residues of the H3 loop. The
ive Gly residues may give the CDR H3 sufficient con-
ormational flexibility to access the membrane surface
hen bound to the membrane-proximal 4E10 epitope
n gp41 (Figure 5B). The H3 loop flexibility would also
llow a potential interaction between the central region
f the loop (ProH100F) and Trp680, a gp41 residue located
nly three residues from the membrane (Figures 4D and
B). Simultaneously, the two Trp residues located at the
ydrophobic tip of the H3 loop (TrpH100 and TrpH100B)
Figure 3C) could enhance the interaction between
E10 and virus by interaction of their side chains with
he viral membrane when the base of the H3 loop en-
ounters the gp41 epitope (see e.g., the proposed
odel in Figure 5B). Biochemical analysis using enve-
ope glycoprotein proteoliposomes suggests that 4E10
nd 2F5 binding is enhanced in the presence of a lipid
embrane (Ofek et al., 2004). Mutagenesis studies of
he H3 loop of 4E10 are ongoing to test the importance
f the CDR H3 for 4E10 binding to gp41 on virus par-
icles.
In addition, 4E10 also has an unusually hydrophobic
2 loop that has the most extensive interactions with
he peptide epitope (41% of total contacts). The largely
ydrophobic nature of these CDR’s H2 and H3 makes
he 4E10 combining site considerably more hydropho-
ic (Figure 3D) than those of most antibodies. Thus,
lucidation of the critical features of 4E10 recognition
f HIV-1 helps to define potential immunogens able to
licit 4E10-like antibodies. For instance, a helical pre-
entation of the core epitope in proximity to a hy-
rophobic environment, such as a membrane, would
ppear to be a useful start for design of a vaccine can-
idate.
xperimental Procedures
ab 4E10 Preparation, Crystallization, and Data Collection
ecombinant IgG1(κ) 4E10 was overexpressed in Chinese hamster
vary cells as previously described (Buchacher et al., 1994; Kunertarallel to the bilayer. Additionally, some degree of conformational
lexibility in the H3 loop may allow Trp100 and Trp100B to interact
ith the membrane. Although, in our structure, Trp100 makes a crys-
al contact that restricts the H3 loop conformational freedom, the
ip of the H3 loop would be expected to be flexible in solution. Also
odeled is an N-terminal extension of the peptide that includes the
djacent 2F5 epitope using its conformation determined from the
rystal structure of the 2F5-peptide complex (PDB entry 1TJI; Ofek
t al., 2004). The 2F5 epitope is positioned such that the face rec-
gnized by antibody (particularly the DKW core epitope) is pointed
way from the viral membrane.
Anti-HIV Antibody 4E10 Recognizes a Helical Motif
171et al., 2000). Antigen binding fragment Fab 4E10 was obtained by
papain digestion of IgG1 4E10. Mercuripapain (Sigma; enzyme at
0.5 mg/ml) was preactivated with 10 mM cysteine and 1.25 mM
EDTA in 0.1 M sodium acetate (pH 5.5) for 15 min at 37°C. Activated
papain solution was then added to IgG1 4E10 (at 5 mg/ml in 0.1 M
sodium acetate [pH 5.5]) to give a final w/w ratio of 4% papain, and
the reaction was incubated at 37°C for 4 hr. Iodoacetamide (20 mM)
was added and followed by further incubation at 37°C for 1 hr to
stop the digestion reaction.
Fab 4E10 was purified to >95% homogeneity using sequential
affinity, size exclusion, and ionic exchange chromatography. Ini-
tially, digested sample was diluted 1:3 with 3.0 M NaCl in 0.1 M
Tris-HCl (pH 9.0) and loaded onto a recombinant protein A column
(Repligen). The nonbound material was diluted 1:3 with 10 mM so-
dium phosphate (pH 7.0), 0.15 M NaCl, 10 mM EDTA and loaded
onto a recombinant protein G Gammabind Plus column (Amersham
Pharmacia). The Fab was eluted using 0.1 M acetic acid (pH 3.0)
and immediately neutralized with 1/10 volume of 1.0 M NaHCO3.
The eluted fractions were pooled, dialyzed against 0.2 M sodium
acetate (pH 5.5), and loaded on a Superdex 75 HR16-60 column
(Amersham Pharmacia) equilibrated in 0.2 M sodium acetate (pH
5.5). The gel-filtrated pooled fractions were further purified by cat-
ion exchange chromatography on a MonoS HR5-5 column (Amer-
sham Pharmacia) with 20 mM sodium acetate (pH 5.5) and a 0–1.0
M NaCl gradient. Pure Fab 4E10 was dialyzed against 20 mM so-
dium acetate (pH 5.5) and concentrated to 12 mg/ml using a Milli-
pore Ultrafree-15 centrifuge concentrator (10 kDa molecular weight
cut-off).
The peptide was synthesized as previously described (Zwick et
al., 2001a) and diluted in water to a concentration of 10 mg/ml.
Crystals of Fab 4E10 in complex with the peptide were obtained by
cocrystallization after overnight preincubation at 4°C of peptide
and Fab 4E10 in a molar ratio of 1:5 (protein:peptide). Crystalliza-
tion conditions for the complex were initially screened in a nano-
drop format (total of 100 nl per drop) using a crystallization robot
(Syrrx). Promising crystallization conditions were identified and op-
timized manually. The best crystals of the complex were grown at
22°C by sitting drop vapor diffusion against 10%–12% (w/v) PEG
8000 in 0.1 M sodium acetate (pH 5.0), 10 mM hexamine cobalt
trichloride. Prior to being cooled to cryogenic temperatures, crys-
tals were soaked in a cryoprotectant solution of mother liquor con-
taining 25% (v/v) glycerol. Data were collected on beamline 9-2 at
the Stanford Synchrotron Radiation Laboratory (SSRL) using a li-
quid nitrogen cryostream maintained at 90 K and processed using
the HKL package (Otwinowski and Minor, 1997) and the CCP4 suite
of programs (CCP4, 1994). Diffraction patterns show the contribu-
tion of more than one crystalline lattice; however, it was possible
to separate and process the diffraction data from the dominant
lattice with good final statistics (Table 1).
Structure Determination and Refinement
The structure of Fab 4E10 as a complex with the 13-residue pep-
tide was determined by molecular replacement using AMoRe (Na-
vaza, 1994) and Fab 48G7 (PDB entry 1HKL) as a probe. The struc-
ture was refined in CNS (Brünger et al., 1998) and REFMAC (CCP4,
1994). Rfree was calculated using the same set of 5% randomly
assigned reflections in both programs. Fab heavy and light chains
were treated separately as rigid bodies for the initial refinement in
CNS. The protein model was then refined using torsion angle simu-
lated annealing at 5000 K. Following these initial stages, the refine-
ment proceeded through cycles of positional, temperature factor,
and manual rebuilding in XFIT (McRee, 1999) into σA-weighted
2Fo − Fc and Fo − Fc electron density omit maps. The maximum
likelihood target function, bulk solvent corrections, and anisotropic
temperature factor corrections were used for the refinement cycles
in CNS. Because the amino acid sequence for the antibody (Kunert
et al., 2004) became available only when structural refinement was
in the last stages, the 4E10 side chains were initially assigned using
information from the Kabat database (Kabat et al., 1991) and the
electron density maps. Based on the final electron density and es-
pecially due to a possible hydrogen bond interaction, light chain
residue 11 was modeled as a Gln in the final structure rather than
a Leu, as indicated by the sequence data. Density for the peptidewas clear after a few cycles of refinement and manual rebuilding
of the starting Fab model. Tight noncrystallographic restraints were
used early on in the refinement and released gradually toward the
end of the refinement. Water molecules were added automatically
using cycles of ARP (CCP4, 1994) for placement and REFMAC with
TLS groups for refinement, then verified by manual inspection in
XFIT. Stereochemical analysis of the refined structure was per-
formed using PROCHECK (CCP4, 1994). Refinement statistics are
summarized in Table 1. One of the molecules of the complex in the
asymmetric unit (molecule 2) has higher B values (40.4 Å2) than the
other (23.3 Å2) due to fewer crystal packing contacts.
Structural Analysis
Superpositions and root-mean-square deviations (rmsd) calcula-
tions were carried out using the INSIGHT II package (Accelrys, Inc.,
San Diego, CA) for pairs of CH1, CL, VH, and VL domains. Hydrogen
bonds between Fab 4E10 and peptide were identified using
HBPLUS (McDonald and Thornton, 1994), and van der Waals con-
tacts were assigned with CONTACSYM (Sheriff et al., 1987). Buried
surface areas were calculated using MS (Connolly, 1993) with a
1.7 Å probe radius and standard van der Waals radii (Gelin and
Karplus, 1979). The LysP680 to TrpP680 change was modeled with
XFIT (McRee, 1999). Secondary structure was assigned using PRO-
MOTIF (Hutchinson and Thornton, 1996). Graphics were prepared
using XFIT (Figures 2, 3E, 3F, 5B, and 5C), RASTER3D (Merritt and
Bacon, 1997) (Figures 2–5), GRASP (Nicholls et al., 1991) (Figures
3D and 5A), and MOLSCRIPT (Kraulis, 1991) (Figures 3A–3D, 4,
and 5).
Binding Affinity by ELISA
Enzyme-linked immunosorbent assays (ELISA) were used to deter-
mine the apparent binding affinity of the antibody for the peptide
and gp41. Microplate wells (Corning) were coated overnight at 4°C
with 50 l of PBS containing peptide (4 g/ml) or recombinant gp41
(4 g/ml). The wells were washed twice with PBS containing 0.05%
Tween 20 and blocked with 3% BSA for 45 min at 37°C. After a
single wash, 4E10 (5 g/ml) was added to the wells in PBS contain-
ing 1% BSA and 0.02% Tween and allowed to incubate at 37°C for
2 hr. The wells were washed four times, goat anti-human IgG
F(ab#)2 alkaline phosphatase (Pierce) diluted 1:500 in PBS contain-
ing 1% BSA was added, and the plate was incubated for 40 min at
room temperature. The wells were washed four times and devel-
oped by adding 50 l of alkaline phosphatase substrate prepared
by adding one tablet of disodium-ρ-nitrophenyl phosphate (Sigma)
to 5 ml of alkaline phosphatase staining buffer (pH 9.8), as specified
by the manufacturer. After 30 min, the optical density at 405 nm
was read on a microplate reader (Molecular Devices).
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